On November 21, 2024, Jason Daly, Senior Vice President and Chief Legal Officer at Amneal Pharmaceuticals Inc, sold 13,665 shares of the company, according to a SEC Filing. Following this transaction, the insider now owns 0 shares of the company. Amneal Pharmaceuticals Inc (AMRX, Financial) is a pharmaceutical company that develops, manufactures, and distributes generic and specialty pharmaceutical products. The company operates in the United States and internationally, focusing on delivering affordable and accessible medications to patients. Over the past year, Jason Daly has sold a total of 57,322 shares and has not purchased any shares. The insider transaction history for Amneal Pharmaceuticals Inc indicates that there have been no insider buys in the past year, while there have been five insider sells. On the day of the recent sale, shares of Amneal Pharmaceuticals Inc were trading at $8.40 each, giving the stock a market cap of $2.6 billion. The stock's GF Value is estimated at $2.51, resulting in a price-to-GF-Value ratio of 3.35. This suggests that the stock is significantly overvalued based on its GF Value. The GF Value is an intrinsic value estimate developed by GuruFocus, calculated using historical multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also considers a GuruFocus adjustment factor based on the company’s past returns and growth, as well as future estimates of business performance from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
